Results 81 to 90 of about 27,289 (199)

Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension

open access: yesSaudi Journal of Kidney Diseases and Transplantation, 2011
To determine the antihypertensive benefit of adding low dose sprinolactone to multi-drug regimens that included a diuretic, a calcium channel blocker and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with moderately ...
Rozita Abolghasmi, Omolbanin Taziki
doaj  

Therapeutic drug monitoring of antimicrobials in a paediatric setting: A retrospective single‐centre study

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2723-2740, August 2026.
Aims Paediatric pharmacokinetics differ significantly from adults due to age‐related physiological changes, necessitating precise dose adjustments. However, data on therapeutic drug monitoring (TDM) implementation in paediatric setting remain limited.
Gianluca Gazzaniga   +20 more
wiley   +1 more source

The Aldosterone Blockade for Health Improvement Evaluation in End-Stage Renal Disease (ACHIEVE) Trial: Rationale and Clinical Research Protocol

open access: yesCanadian Journal of Kidney Health and Disease
Background: The mineralocorticoid aldosterone may contribute to the risk of cardiovascular morbidity and mortality in patients receiving maintenance dialysis. Whether spironolactone, a mineralocorticoid receptor antagonist, improves outcomes for patients
Michael Walsh   +24 more
doaj   +1 more source

Contraindicated drug–drug interactions and associated adverse drug reactions in an observational cohort study of 4543 paediatric hospitalized patients

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2834-2852, August 2026.
Abstract Background and Purpose Drug–drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequent use of unlicensed or off‐label medications, and dosing regimens often extrapolated from adult data.
Emilie Laval   +6 more
wiley   +1 more source

Effects of Spironolactone on Proteinuria of Patients with Type 2 Diabetes

open access: yesمجله دانشکده پزشکی اصفهان, 2012
Background: Diabetic nephropathy is the most common cause of kidney failure. We investigated the beneficial effects of spironolactone, alone and in combination with hydrochlorothiazide, on diabetic nephropathy.
Mohamad Karami Horestani   +3 more
doaj  

Impella‐Assisted High‐Risk Percutaneous Coronary Intervention in Cardiogenic Shock With Low‐Flow, Low‐Gradient Aortic Stenosis and Multivessel Coronary Artery Disease: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Patients with cardiogenic shock, low‐flow, low‐gradient aortic stenosis, and multivessel coronary artery disease who are ineligible for surgery present a major therapeutic challenge. Percutaneous mechanical circulatory support may facilitate revascularization in this high‐risk population. A 69‐year‐old man presented after a mechanical fall and
Douni Roger   +3 more
wiley   +1 more source

Efficacy and Safety of Low‐Dose Spironolactone in Management of Diabetic Kidney Disease in a Real‐World Setting

open access: yesEndocrinology, Diabetes & Metabolism
Background Adding spironolactone to renin‐angiotensin‐aldosterone system (RAAS) blockers has been shown to reduce albuminuria in patients with diabetic kidney disease (DKD). However, the increased risk of hyperkalaemia is a major concern.
Manochehr Amini   +5 more
doaj   +1 more source

Medications That Regulate Pregnane X Receptor: A Systematic Review of Current Evidence

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
PRISMA 2020 flow diagram of study selection for this systematic review of medications that regulate the pregnane X receptor (PXR), from 12 236 records screened to 101 included studies. ABSTRACT The pregnane X receptor (PXR) gene encodes a ligand‐activated protein involved with the metabolism and excretion of drugs, toxins, and other xenobiotics.
Petra Czarniak   +4 more
wiley   +1 more source

Medication Burden: Beyond Counts to Recognize Polypharmacy as an Inherent Part of Living With Chronic Kidney Disease

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 139, Issue 2, August 2026.
ABSTRACT Medication burden in older patients with chronic kidney disease (CKD) is substantial, and simple medication counts are insufficient for identifying those at elevated risk of inappropriate prescribing. This study characterized medication burden by assessing the number of medications, potentially inappropriate medications (PIMs) and ...
Morten Baltzer Houlind   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy